News | October 09, 2025
Briefs: Panacea Biotec and Shukra Pharmaceuticals
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives acceptance from CMSS for supply of bOPV
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
New study presents a human-relevant stress model for assessing potential therapeutics
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Subscribe To Our Newsletter & Stay Updated
